All In Biotech

Drug Trial Radar · NCT06088888

TGRX-678 US Phase I for Chronic Myelogenous Leukemia Patients

An Open-label, Dose Escalation + Dose Expansion Phase 1 Trial to Determine the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-678 Given Orally to Patients With Chronic Myeloid Leukemia Who Are Resistant or Intolerant to TKI Treatments

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jul 2, 2024

Primary completion

Dec 31, 2027

Study completion Feb 29, 2028

Sponsor

Lead sponsor
Shenzhen TargetRx Co., Ltd.Industry
Sponsor type
Industry
Collaborators
M.D. Anderson Cancer Center
First posted
Oct 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this single-arm, open-label, dose escalation + cohort expansion study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.

Conditions

  • Chronic Myelogenous Leukemia

Interventions

  • TGRX-678Drug

    Participants are given TGRX-678 tablets orally, once daily, at one of the dose levels as pre-determined for the dose escalation sequence or expansion cohorts.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended dose for expansion (RDE)Time frame: Time Frame: At end of Dose Escalation part of study, an average of 1 year
  2. Safety profile (DLT)Time frame: Time Frame: DLT: collect during Cycle 1 (28 days)
  3. Safety profile (AEs/SAEs)Time frame: AE and SAE: through completion of the study, an average of 2 years
  4. Recommended phase II dose (RP2D)Time frame: At completion of the study, an average of 2 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.